Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes

作者：Ko Jennifer S; Matharoo Ball Balwir; Billings StevenD; Thomson Brian J; Tang Jean Y; Sarin Kavita Y; Cai Emily; Kim Jinah; Rock Colleen; Kimbrell Hillary Z; Flake Darl D II; Warf M Bryan; Nelson Jonathan; Davis Thaylon; Miller Catherine; Rushton Kristen; Hartman Anne Renee; Wenstrup Richard J; Clarke Loren E^*

来源：Cancer Epidemiology Biomarkers & Prevention, 2017, 26(7): 1107-1113.

DOI：10.1158/1055-9965.EPI-16-0958

Background: Histopathologic examination alone can be inadequate for diagnosis of certain melanocytic neoplasms. Recently, a 23-gene expression signature was clinically validated as an ancillary diagnostic test to differentiate benign nevi from melanoma. The current study assessed the performance of this test in an independent cohort of melanocytic lesions against clinically proven outcomes.
Methods: Archival tissue from primary cutaneous melanomas and melanocytic nevi was obtained from four independent institutions and tested with the gene signature. Cases were selected according to pre-defined clinical outcome measures. Malignant lesions were defined as stage I-III primary cutaneous melanomas that produced distant metastases (metastatic to sites other than proximal sentinel lymph node(s)) following diagnosis of the primary lesion. Melanomas that were metastatic at the time of diagnosis, all re-excisions, and lesions with <10% tumor volume were excluded. Benign lesions were defined as cutaneous melanocytic lesions with no adverse long-term events reported.
Results: Of 239 submitted samples, 182 met inclusion criteria and produced a valid gene expression result. This included 99 primary cutaneous melanomas with proven distant metastases and 83 melanocytic nevi. Median time to melanoma metastasis was 18 months. Median follow-up time for nevi was 74.9 months. The gene expression score differentiated melanoma from nevi with a sensitivity of 93.8% and a specificity of 96.2%.
Conclusions: The results of gene expression testing closely correlate with long-term clinical outcomes of patients with melanocytic neoplasms.

• 出版日期2017-7